Home > Oncology > SABCS 2019 > Letter from the Editor

Letter from the Editor

Dr Stefan Rauh, Centre Hospitalier Emile Mayrisch, Esch, Luxembourg
SABCS 2019

Dear Reader,

I hope you will enjoy our issue summing up the 2019 San Antonio Breast Cancer Symposium (SABCS), which took place last December 10-14.

Could we spare our patients surgery in case that high-performing imaging and biopsies confirm complete remissions? Can predictive gene assays totally replace clinical features in early breast cancer? Hormone replacement in post-menopausal women: is the ban about to be lifted? You will find very interesting studies talking about these questions in the following chapter.

Concerning treatment of active disease, you will find a second oral fluoropyrimidine, an oral taxane, pertuzumab joining the subcutaneous injectables, and new drugs for refractory metastatic HER2 breast cancers coming on the scene. The role of immunotherapy in triple-...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on